Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 6958-6961

  Bender, David M ^a   Bao, Jingqi ^a   Dantzig, Anne H ^a   Diseroad, William D ^a   Law, Kevin L ^a   Magnus, Nicholas A ^a   Peterson, Jeffrey A ^a   Perkins, Everett J ^a   Pu, Yangwei J ^a   Reutzel Edens, Susan M ^a   Remick, David M ^a   Starling, James J ^a   Stephenson, Gregory A ^a   Vaid, Radhe K ^a   Zhang, Deyi ^a   McCarthy, James R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2, 5' O ISOLEUCINE GEMCITABINE; ACICLOVIR; ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE KINASE; FLUOROURACIL; GEMCITABINE; LY 2334737; UNCLASSIFIED DRUG; VALACICLOVIR; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; CYTOTOXICITY; DEAMINATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME STABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HYDROLYSIS; INTESTINE MUCOSA; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PROTEIN PHOSPHORYLATION; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; CYTIDINE; DEOXYCYTIDINE; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PRODRUGS; SOLUBILITY;

EID: 70949086288     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901181h     Document Type: Article

References (22)

1. (a) Hertel, L. W.; Boder, G. B.; Kroin, J. S.; Rinzel, S. M.; Poore, G. A.; Todd, G. C.; Grindey, G. B. Cancer Res. 1990, 50, 4417-4422.
2. (b) Eckel, F.; Schneider, G.; Schmid, R. M. Pancreatic cancer: a review of recent advances. Expert Opin. Invest. Drugs 2006, 15, 1395-1410.
3. (c) Manegold, C. Gemcitabine (Gemzar) in non-small cell lung cancer. Expert Rev. Anticancer Ther. 2004, 4, 345-360.
4. (d) Heinemann, V. Gemcitabine in metastatic breast cancer. Expert Rev. Anticancer Ther. 2005, 5, 429-443.
5. (a) Huang, P.; Chubb, S.; Hertel, L.; Grindey, G.; Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991, 51, 6110-6117.
6. (b) Ruiz van Haperen, V.; Vererman, G.; Vermorken, J.; Peters, G. 2′,2′-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem. Pharmacol. 1993, 46, 762-766.
7. (c) Heinemann, V.; Xu, Y.; Chubb, S.; Sen, A.; Hertel, L.; Grindey, G.; Plunkett, W. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992, 52, 533-539.
8. (a) Shipley, L.; Brown, T.; Cornpropst, J.; Hamilton, M.; Daniels, W.; Culp, H. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab. Dispos. 1992, 20, 849-855.
9. (b) Kroep, J.; van Moorsel, C.; Veerman, G.; Voorn, D.; Schultz, R.; Worzalla, J.; Tanzer, L.; Merriman, R.; Pinedo, H.; Peters, G. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC). Adv. Exp. Med. Biol. 1998, 431, 657-660.
10. (a) Veltkamp, S. A.; Beijnen, J. H.; Schellend, J. H. H. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist 2008, 13, 261-276.
11. (b) Patel, S. R.; Gandhi, V.; Jenkins, J.; Papadopolous, N.; Burgess, M. A.; Plager, C.; Plunkett, W.; Benjamin, R. S. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin. Oncol. 2001, 19, 3483-3489.
12. (c) Grunewald, R.; Abbruzzese, J. L.; Tarassoff, P.; Plunkett, W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother. Pharmacol. 1991, 27, 258-262.
13. (d) Grunewald, R.; Kantarjian, H.; Keating, M.; Abbruzzese, J.; Tarassoff, P.; Plunkett, W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res. 1990, 50, 6823-6826. (Pubitemid 20361074)
14. (e) Eckel, F.; Schmelz, R.; Erdmann, J.; Mayr, M.; Lersch, C. Phase II trial of a 24-h infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest. 2003, 21, 690-694. (Pubitemid 37377323)
15. Horton, N. D.; Young, J. K.; Perkins, E. J.; Truex, L. T. Toxicity of Single-Dose Oral Gemcitibine in Mice. Presented at the Meeting of the American Association for Cancer Research, Orlando, FL, March 27-31, 2004; Abstract 2115.
16. Shimma, N.; Umeda, I.; Arasaki, M.; Murasaki, C.; Masubuchi, K.; Kohchi, Y.; Miwa, M.; Ura, M.; Sawada, N.; Tahara, H.; Kuruma, I.; Horii, I.; Ishitsuka, H. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg. Med. Chem. 2000, 8, 1697-1706.
17. (a) Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned frommarketed and investigational prodrugs. J. Med. Chem. 2004, 47, 2393-2404.
18. (b) MacDougall, C.; Guglielmo, J. Pharmacokinetics of valaciclovir. J. Antimicrob. Chemother. 2004, 53, 899-901.
19. Song, X.; Lorenzi, P. L.; Landowski, C. P.; Balvinder, S. V.; Hilfdinger, J. M.; Amidon, G. L. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT-1 mediated transport. Mol. Pharmaceutics 2004, 2, 157-167.
20. 4-(α-aminoacyl)cytidines to N-(4-citidinyl) amino acid amides. Tetrahedron Lett. 2008, 49, 2052-2055.
21. Guo, Z.-w.; Gallo, J. M. Selective protection of 2′,2′- difluorodeoxycytidine (gemcitabine). J. Org. Chem. 1999, 64, 8319-8322.
22. Šponer, J.; Leszczynski, J.; Vetterl, V.; Hobza, P. Base stacking and hydrogen bonding in protonated cytosine dimer: the role of molecular ion-dipole and induction interactions. J. Biomol. Struct. Dyn. 1996, 13, 695-706.